Patents by Inventor Mark D. Alter

Mark D. Alter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic and diagnostic cloned MHC-unrestricted receptor specific for the MUC1 tumor associated antigen
    Patent number: 11325962
    Abstract: The invention provides an isolated nucleic acid encoding a receptor, other than an immunoglobulin, wherein the receptor binds to a MUC1 tumor antigen independently of an major histocompatibility complex (MHC). The invention provides a method of activating a signaling pathway and/or killing a cancer cell using a receptor that is similar to or is a T cell receptor.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: May 10, 2022
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Olivera J. Finn, Nehad M. Alajez, Jan Schmielau, Mark D. Alter
  • THERAPEUTIC AND DIAGNOSTIC CLONED MHC-UNRESTRICTED RECEPTOR SPECIFIC FOR THE MUC1 TUMOR ASSOCIATED ANTIGEN
    Publication number: 20190276514
    Abstract: The invention provides an isolated nucleic acid encoding a receptor, other than an immunoglobulin, wherein the receptor binds to a MUC 1 tumor antigen independently of an major histocompatibility complex (MHC).
    Type: Application
    Filed: March 27, 2019
    Publication date: September 12, 2019
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Olivera J. Finn, Nehad M. Alajez, Jan Schmielau, Mark D. Alter
  • THERAPEUTIC AND DIAGNOSTIC CLONED MHC-UNRESTRICTED RECEPTOR SPECIFIC FOR THE MUC1 TUMOR ASSOCIATED ANTIGEN
    Publication number: 20170022264
    Abstract: The invention provides an isolated nucleic acid encoding a receptor, other than an immunoglobulin, wherein the receptor binds to a MUC1 tumor antigen independently of an major histocompatibility complex (MHC).
    Type: Application
    Filed: October 7, 2016
    Publication date: January 26, 2017
    Inventors: Olivera J. Finn, Nehad M. Alajez, Jan Schmielau, Mark D. Alter
  • Therapeutic and diagnostic cloned MHC-unrestricted receptor specific for the MUC1 tumor associated antigen
    Patent number: 9469684
    Abstract: The invention provides an isolated nucleic acid encoding a receptor, other than an immunoglobulin, wherein the receptor binds to a MUC1 tumor antigen independently of an major histocompatibility complex (MHC). The invention provides a method of activating a signaling pathway and/or killing a cancer cell using a receptor that is similar to or is a T cell receptor.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: October 18, 2016
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Olivera J. Finn, Nehad M. Alajez, Jan Schmielau, Mark D. Alter
  • THERAPEUTIC AND DIAGNOSTIC CLONED MHC-UNRESTRICTED RECEPTOR SPECIFIC FOR THE MUC1 TUMOR ASSOCIATED ANTIGEN
    Publication number: 20130289261
    Abstract: The invention provides an isolated nucleic acid encoding a receptor, other than an immunoglobulin, wherein the receptor binds to a MUC1 tumor antigen independently of an major histocompatibility complex (MHC).
    Type: Application
    Filed: July 11, 2013
    Publication date: October 31, 2013
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Olivera J. Finn, Nehad M. Alajez, Jan Schmielau, Mark D. Alter
  • Therapeutic and diagnostic cloned MHC-unrestricted receptor specific for the MUC1 tumor associated antigen
    Patent number: 7655461
    Abstract: The invention provides an isolated nucleic acid encoding a receptor, other than an immunoglobulin, wherein the receptor binds to a MUC1 tumor antigen independently of an major histocompatibility complex (MHC). The invention provides a method of activating a signaling pathway and/or killing a cancer cell using a receptor that is similar to or is a T cell receptor.
    Type: Grant
    Filed: December 7, 2005
    Date of Patent: February 2, 2010
    Assignee: University of Pittsbugh — Of the Commonwealth System of Higher Education
    Inventors: Olivera J. Finn, Nehad M. Alajez, Jan Schmielau, Mark D. Alter
  • THERAPEUTIC AND DIAGNOSTIC CLONED MHC-UNRESTRICTED RECEPTOR SPECIFIC FOR THE MUC1 TUMOR ASSOCIATED ANTIGEN
    Publication number: 20090081172
    Abstract: The invention provides an isolated nucleic acid encoding a receptor, other than an immunoglobulin, wherein the receptor binds to a MUC1 tumor antigen independently of an major histocompatibility complex (MHC).
    Type: Application
    Filed: October 27, 2008
    Publication date: March 26, 2009
    Applicant: University of Pittsburgh of the Commonwealth System of Higher Education
    Inventors: Olivera J. Finn, Nehad M. Alajez, Jan Schmielau, Mark D. Alter